Note: Information provided may change and should not be used as a substitute for individual evaluation by a health care provider, or as the primary means […]

FDA recognizes the increased use of artificial intelligence and machine learning (AI/ML) throughout the drug development life cycle and its potential to accelerate this process. For […]

The Food and Drug Administration is advising consumers not to purchase or use SILI PHARMA, a product promoted and sold for pain on various websites, including https://botanical-be.com, […]

The Food and Drug Administration is advising consumers not to purchase or use RMSOL GRACIAN, a product promoted and sold for pain on various websites, including https://botanical-be.com […]

For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the […]

[7/30/2024] FDA is warning consumers not to purchase or use certain chemical peel skin products without appropriate professional supervision due to risk of serious skin injuries. The […]

Drug shortages impact patients, health care providers, and the overall health care system. This infographic provides a overview of the drug shortage landscape in 2023, the […]

Discover educational resources available under the QM CoE. FDA/C-Path Institute Model Informed Drug Development Web-Based Training The U.S. Food and Drug Administration’s (FDA’s) Center for Drug […]

How do I report adverse events associated with the use of a drug? FDA’s MedWatch Web site provides various means for voluntary reporting of serious postmarketing […]